Having trouble viewing this email? View in a browser.

You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.

Formulary

Formulary News Capsule

FormularyJournal.com

February 17, 2012

DIABETES MANAGEMENT

ACP recommends metformin as first-line therapy for type 2 diabetes

Physicians should prescribe oral metformin as a first-line therapy for most patients with type 2 diabetes, as well as for those whose blood sugar cannot be controlled with diet, exercise, and weight loss, according to new guidelines from the American College of Physicians. » More

Poorly controlled diabetes may lead to hearing loss in women

Uncontrolled diabetes may result in hearing loss in women, much like it affects vision or kidney function, according to the results of a new study. » More

Editor's Pick

Orally inhaled dihydroergotamine: A novel ergot delivery method for the treatment of migraine

Orally inhaled dihydroergotamine (DHE) is a newly developed formulation of DHE for the treatment of acute migraine attack and is undergoing FDA review. This new agent provides an alternative to nonsteroidal anti-inflammatory drugs and triptans. In clinical trials, orally inhaled DHE was effective compared with placebo in relieving headache, nausea, phonophobia, and photophobia. » Click here.

CONTINUING EDUCATION

Cardiometabolic disease: The pharmacist’s role in managing weight loss and medication adherence

Pharmacists can help with the management of weight loss through nutrition education, exercise counseling, and strategies for medication adherence.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login and take the exams.

HEALTH SYSTEMS

Shortage of anti-infective drugs needs government attention, authors say

Anti-infective drug shortages pose significant problems for clinicians and are a rapidly evolving public-health emergency that may require government oversight, according to an article published online January 19 in Clinical Infectious Diseases. » More

CLINICAL NEWS

Study finds association between open-angle glaucoma and ED

Men with ED also were more likely to have had open-angle glaucoma than those without ED, according to a study published in the February 12 online issue of Ophthalmology.
» More

FDA ACTIONS

FDA extends approval for drug to treat adult ADHD

FDA has approved lisdexamfetamine dimesylate (Vyvanse, Shire) capsules, (CII) as a maintenance treatment for adults with ADHD. Vyvanse was already approved as a treatment for ADHD in patients aged 6 to 17 years. » More

FDA grants priority review to breast-cancer therapy pertuzumab

FDA has granted priority review to pertuzumab (Genentech, a member of the Roche Group) in combination with trastuzumbab (Herceptin, Genentech) and docetaxel chemotherapy for certain breast-cancer patients. » More

PBM NEWS

Medco launches program to improve management of costs for specialty drugs

Medco Health Solutions and its Accredo Health Group specialty pharmacy have launched a program for employers to better manage specialty-drug costs within major medical coverage. » More

Survey

Who performs medication therapy management (MTM) or medication reconciliation in your health system?

1)  A nurse or nurse case manager performs MTM in my health system

2)  A physician performs MTM or medication reconciliation in my health system

3)  A pharmacist performs MTM or medication reconciliation in my health system

4)  More than 1 different type of healthcare provider performs MTM and/or medication reconciliation in my health system

Respond here and see what your colleagues think too.

Want to see the results of our last survey regarding the use of aliskiren-containing medications? Click here.

Twitter  

Follow us on Twitter

Resources

Drug Watch

FDA Actions

Latest News

Medication Safety

Policy Watch

Digital Edition

View current edition

Cover
 
Powered by Modern Medicine Advanstar Medical Communications Group
 

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.